BirchBioMed Receives Health Canada Approval for Topical Cream (NPN 80147114)
U.S. FDA Grants BirchBioMed Orphan Drug Designation for FS2 in the Treatment of Idiopathic Pulmonary Fibrosis
HHS Centre for Burn Research Leads National Trial for Scar Treatment
BioNexus Gene Lab Corp Signs Strategic Partnership Term Sheet with BirchBioMed Inc.
BirchBiomed Launches Pivitol Phase II / III Pioneering Scar Treatment Trial In Burns With Hamilton Health Sciences’ Centre For Burn Research In Ontario
BirchBioMed Receives Health Canada Green Light to Start the Last Stage of its Groundbreaking Clinical Program of FS2 to Minimize Scarring from Burns
BirchBioMed Welcomes Dr. Carlos Roberto Camozzi as Chief Medical Officer
BirchBioMed Welcomes Hervé Girsault as Chief Business Officer
BirchBioMed Welcomes Dr. Jonathan Bourne as New Chief Science Officer
Innovation in Treatment of Keloid Scars
“Topical FS2 for Mature Keloid Scars” Mark Steven Nestor, M.D., Ph.D. Director Center for Cosmetic Enhancement, Center for Clinical and Cosmetic Research, Aventura Florida Voluntary Professor Department of Dermatology and Cutaneous Surgery Department of Surgery, Division of Plastic Surgery University of Miami Miller School of Medicine